-
Dual-mTOR inhibitor Rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity
Study
EGAS00001004431
-
RRBS data from TRACERx non-small cell lung cancer (NSCLC) tumours and matched normal adjacent tissue.
Study
EGAS00001006523
-
The Landscape of N-6 Methyladenosine in Primary Localized Prostate Cancer
Study
EGAS00001006925
-
Epithelioid haemangioendothelioma (EHE) case series from the Stafford Fox Rare Cancer Program
Study
EGAS00001007474
-
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer
Study
EGAS00001007291
-
WGS
Study
EGAS00001007211
-
RNA Sequence-Based Analysis Used to Compare Breast Primary and Metastatic Tumor Pairs
Study
phs001866
-
Angiopredict: predicting response for bevacizumab treatment
Study
EGAS00001002724
-
cell-Free DNA Genomic Profiling and its Clinical Implementation in Advanced Prostate Cancer
Study
EGAS50000000234
-
Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer
Study
EGAS50000000775